Navigation Links
Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
Date:10/23/2011

ting multiple cellular pathways and processes. By coordinating the expression of multiple genes, miRNAs are responsible for guiding proper embryonic development, immunity, inflammation, as well as cellular growth and proliferation. Misregulation of miRNAs appears to play a fundamental role in many cancers and replacement of down regulated miRNAs in tumor cells results in a positive therapeutic response

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

For further information, please contact:
       
Silence Therapeutics
Thomas Christély/Max Herrmann
+49-30-9489-2800/+44-20-7491-6520
t.christely@silence-therapeutics.com
m.herrmann@silence-therapeutics.com

Singer Capital Markets
Shaun Dobson/Claes Spång
+44-20-32057500
shaun.dobson@singercm.com
claes.spang@singercm.com
                   
Mirna Therapeutics
Paul Lammers, MD
+1-512-901-0909
plammers@mirnarx.com

M:Communications (Europe)
Peter Laing / Emma Thompson
+44-20-7920-2345 / +44-20-7920-2342
healthcare@mcomgroup.com

Vida Communication (
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
2. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
3. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
4. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Silence Therapeutics Appoints New Vice President of Research
8. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
9. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
10. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
11. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Advanced Pain Remedies (APR), a subsidiary of Cato ... been received, to advance its lead development candidate, SP-SAP. ... of specific cell types to manipulate them for the ... grant from the National Cancer Institute (NCI). Advanced Targeting ...
... Group, Inc. (MDXG), an integrated developer, manufacturer and marketer of ... at the 13th Annual Needham Growth Conference in New York. ... President and COO, and Michael J. Senken, CFO of MiMedx, ... a.m. Eastern Time at the New York Palace Hotel in ...
... 2011 Sutro Biopharma, a biopharmaceutical company developing ... properties, today announced that the company has entered ... research, development and commercialization of novel peptide-based therapeutics. ... Sutro Biopharma will receive an upfront payment of ...
Cached Biology Technology:Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP 2Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP 3Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics 2
(Date:7/9/2014)... increase the survival rate of naturally aged animals? ... Pharmaceutical Sciences, Southwest University, China performed an animal ... low dose of levothyroxine for 3 consecutive months. ... obvious improvement in cognitive and an increased rat ... mechanism was demonstrated that levothyroxine treatment can increase ...
(Date:7/9/2014)... southern Europe are less fit in terms of ... European peers. Moreover, southern adolescents are more obese ... fat than those from the centre-north of Europe. ... from an ambitious study conducted by scientists from ... in collaboration with 25 other European research groups. ...
(Date:7/9/2014)... They are amongst the most numerous inhabitants of the ... . Not visible to the naked eye, when they ... sized patches, they are even visible on satellite images. ... responsible for approximately half of the global photosynthesis output," ... University Jena (Germany). In the process the greenhouse gas ...
Breaking Biology News(10 mins):Adolescents from southern Europe are less fit and more obese than central-northern European peers 2Short circuit in the food web 2
... clue to the causes of autism and mental retardation ... rapidly transfers information from one neuron to the next. ... with students from the Sackler School of Graduate Biomedical ... coli) plays a key role in synapse maturation, and ...
... , CAMBRIDGE, Mass. -- Human pluripotent stem cells, which can ... to treat a wide range of ailments, including Parkinson,s disease, ... with such cells have had trouble growing large enough quantities ... human studies. Furthermore, most materials now used to grow ...
... Mutations in a single gene can cause several ... considered different disorders. With support from the National ... exome sequencing a new gene scanning technology that ... mutations. "This is going to change the way ...
Cached Biology News:Researchers connect APC protein to autism and mental retardation 2MIT researchers develop a better way to grow stem cells 2MIT researchers develop a better way to grow stem cells 3Gene scan finds link across array of childhood brain disorders 2Gene scan finds link across array of childhood brain disorders 3
... Medium is formuatled for the growth ... and Sf21 cells. Grace's Insect Mediu, ... it does not contain lactalbumin hydrosylate, ... transfection. Grace's Insect Medium, Supplemented is ...
D.R. Harper and C. Grose (1994) • Includes: virus structure & replication, fundamental virology, immunology and pathogenesis, vaccines and antiviral drugs, novel diagnostic techniques, cloning a...
...
...
Biology Products: